This isn't dangerous, but intradermal administration produces erratic absorption and localized irritation because the dermis lacks the vascular and lymphatic network that governs SubQ pharmacokinetics
Website intended for a New Zealand health professional readership +News Goodfellow Symposium 2026 Watch out for vision loss in patients taking GLP-1 agonists, CARM warns Wednesday 8 April 2026, 03:58 PM New Zealands Centre for Adverse Reactions Monitoring has received reports of persistent visual loss in patients taking GLP-1 agonists [Image: engin akyurt on Unsplash] News archive How to Treat Rare disorders For people with rare disorders, supportive, long-term, consistent and accessible contact with primary care is central and essential
Best for: People prone to colds, flu, or anyone wanting extra protection during high-risk seasons
Patients who use HCG injections as part of a well-structured program gain the advantage of clear guidelines and pharmacy support
Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects
